Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 20.8% | 89.4% | 161% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 86.1% | 96.6% | 95.6% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -125.8% | -168.6% | -417.9% | -1,163.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -132.4% | -189.3% | -423.3% | -1,226.2% |
| EPS Diluted | -0.7 | -0.83 | -0.99 | -1.1 |
| % Growth | 15.7% | 16.2% | 10% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |